MABLOC, LLC
Biotech · Private
Neutralizing monoclonal antibodies (nmAbs) for treatment and prevention of flavivirus infections (yellow fever, dengue, Zika, Ebola)
- Grants
- $3.3M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 2 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Learning from the Ebola success: Can a mAb also save lives after yellow fever infection? | $299,598 | |
| Federal grant | Department of Health and Human Services · Phase II · Learning from the Ebola success: Can a mAb also save lives after yellow fever infection? | $999,410 | |
| Federal grant | Department of Health and Human Services · Phase II · Learning from the Ebola success: Can a mAb also save lives after yellow fever infection? | $988,498 | |
| Federal grant | Department of Health and Human Services · Phase II · Learning from the Ebola success: Can a mAb also save lives after yellow fever infection? | $978,679 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3188 | SYNTHOMICS, INC. | — | — |
| 3189 | DISCOVERY LABORATORIES, INC. | — | — |
| 3190 | CAMINO PHARMA, LLC | — | — |
| 3191 | MABLOC, LLC | — | — |
| 3192 | Armo Biosciences | — | — |
| 3193 | ANCILIA, INC. | — | — |
| 3194 | AIMRNA, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Anti-yellow Fever Virus Antibodies, And Methods Of Their Generation And Usegranted
- ANTI-SARS-COV-2 Antibody Compositions And Uses Thereofapplication
- Anti-yellow Fever Virus Antibodies, And Methods Of Their Generation And Useapplication
- Anti-yellow Fever Antibodies, And Methods Of Their Generation And Usegranted
- ANTI-SARS-COV-2 Antibody Compositions And Uses Thereofapplication
- ANTI-SARS-COV-2 Antibody Compositions And Uses Thereofapplication
- Anti-yellow Fever Virus Antibodies, And Methods Of Their Generation And Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.